A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV

Inclusion Criteria: * Participants need to be between 18 and 65 years old. * Participants must have access to a participating clinical research site and be willing to follow the study schedule. * Participants should understand the study details and be willing to give informed consent. * Participants must agree not to join any other clinical trials until they finish this study. * Participants must be willing to receive HIV test results. * Participants should be open to discussing HIV prevention. * Clinic staff should assess participants as having a low risk of getting HIV, and participants must commit to avoiding high-risk behaviors during the study. * Hemoglobin: Participant meets minimum levels depending on gender and hormone therapy status. * White Blood Cells (WBC): Should be within the normal range or approved by a site clinician. * Platelets: At least 100,000 cells/mm³. * Alanine aminotransferase (ALT): Less than 5 times the upper normal limit. * Creatinine: Less than 1.8 times the upper normal limit or less than 1.5 times your baseline level. * Participants must test negative for HIV-1 and HIV-2. * Participants urine protein must be negative or trace. Reproductive Status: * Participants of child-bearing potential need a negative pregnancy test within 72 hours before starting the study. * Participants must agree to use effective birth control from at least 21 days before joining the study until the end of the study. * Participants must agree not to try to become pregn…